Home » Pipeline
Pipeline
July 26, 2021
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Organicell Regenerative Medicine | Zofin | COVID-19 long-haulers | IND approved by the FDA for phase 1/2 trial |
| Viracta Therapeutics | nanatinostat and valganciclovir | EBV+ recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV+ solid tumors. | IND approved by the FDA for a phase 1b/2 trial |
| YishengBio | PIKA recombinant COVID-19 vaccine | COVID-19 prevention | IND approved by the United Arab Emirates Ministry of Health & Prevention |
| KeifeRx | Nilotinib BE | dementia due to Alzheimer's disease | IND approved by the FDA for phase 3 trial |
| Antengene | ATG-101 | metastatic/advanced solid tumors and B-cell nonHodgkin's lymphoma | phase 1 trial authorized by the Bellberry Human Research Ethics Committee in Australia |
| Ascletis Pharma | ASC40 combined with bevacizumab | recurrent glioblastoma | phase 3 trial authorized by China’s National Medical Products Administration |
| InDex Pharmaceuticals | cobitolimod | moderate-to-severe left-sided ulcerative colitis | phase 3 trial authorized by the Swedish Medical Products Agency |
| Advaxis | ADXS-504 | patients with biochemically recurrent prostate cancer | initiation of phase 1 trial |
| Synlogic | SYNB1934 | phenylketonuria | initiation of phase 1 trial |
| Eureka Therapeutics | ECT204 | hepatocellular carcinoma | initiation of phase 1/2 trial |
| Prometheus Biosciences | PRA023 | moderate-to-severe ulcerative colitis | initiation of phase 2 trial |
| Vertex Pharmaceuticals | VX-548 | acute pain following abdominoplasty surgery | initiation of phase 2 trial |
| Vir Biotechnology | VIR-2218 and VIR-3434 | chronic hepatitis B virus | initiation of phase 2 trial |
| Rain Therapeutics | milademetan (RAIN-32) | de-differentiated liposarcoma | initiation of phase 3 trial |
| Albireo Pharma | Bylvay (odevixibat) | progressive familial intrahepatic cholestasis | approved by the FDA |
| Astellas | Prograf (tacrolimus) | prevention of organ rejection in adult and pediatric lung transplant recipients | approved by the FDA for expanded indication |
| Kadmon Holdings | Rezurock (belumosudil) | patients 12 years and older with chronic graft-vs.-host disease | approved by the FDA |
| Merck | Vaxneuvance (pneumococcal 15-valent conjugate vaccine) | active immunization against invasive pneumococcal disease in adults caused by 15 serotypes | approved by the FDA |
| Merck Eisal |
Keytruda (pembrolizumab) plus Lenvima (lenvatinib) | advanced endometrial carcinoma | approved by the FDA |
| Octapharma USA | Octagam 10 percent intravenous immunoglobulin | adult dermatomyositis | approved by the FDA |
| Nevro | Senza system | chronic pain associated with painful diabetic neuropathy | approved by the FDA |
| bluebird bio | Skysona (elivaldogene autotemcel, Lenti-D gene therapy) | treatment of patients under age 18 who have early cerebral adrenoleukodystrophy without matched sibling donor | approved by the European Commission |
| Astra Zeneca Merck |
Koselugo (selumetinib) | symptomatic, inoperable plexiform neurofibromas in children under age three with neurofibromatosis type 1 | approved by the European Commission |
| Myovant Sciences | Ryeqo (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) | uterine fibroids | approved by the European Commission |
| Regeneron Pharmaceuticals | Ronapreve (casirivimab and imdevimab) | mild-to-moderate COVID-19 | approved in Japan |
Upcoming Events
-
28Sep
-
12Oct
-
18Oct
-
16Nov
